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Introduction  
 
Upper gastrointestinal bleeding (UGIB) is a common gastrointestinal (GI) 
emergency  and mortality rates of 5% to 11% have been reported 
representing a serious and life-threatening entity, despite advances in 
diagnosis and treatment. 
• The epidemiology of  UGIB varies among population and there is a 
paucity of data on UGIB and the factors associated with morbidity and 
mortality from India. 
• This study was planned with an aim to identify clinical and endoscopic 
profile of patients with UGIB coming to our hospital, which is a tertiary 
referral center and to study the factors associated with etiology, morbidity 
and mortality. 
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Aim of the Study 
 
 To determine the common etiologies of upper gastrointestinal bleeding in 
patients presenting to GRH 
 To evaluate variceal bleed as an initial presenting feature in chronic liver 
disease patients .  
 To assess the risk factors associated with rebleed and mortality using 
scoring system. 
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Review of literature  
 
Gastrointestinal (GI) bleeding is a common problem in emergency 
medical practice and should be considered potentially life threatening until 
proven otherwise. 
Upper GI bleeding is defined as that originating proximal to the ligament of 
Treitz, whereas lower GI bleeding originates more distally. Clinically it is 
differentiated with the presenting symptoms and further investigations are done 
to confirm with simultaneous resuscitation and supportive treatment. 
Ligament OF TREITZ is formed by a fold of peritoneum over the suspensory 
muscle of the duodenum. It is an anatomical landmark used to denote the 
duodenojejunal junction and the point where the small intestine passes from 
retroperitoneal duodenum to intraperitoneal jejunum. Clinicians use this as a 
reference to classify upper and lower gastrointestinal bleed. 
Gastrointestinal bleeding can be occult or overt .Overt bleeding is manifested as 
hematemesis, melena or hematochezia. 
 Hematemesis is vomiting out of blood, bright red to coffee brown coloured . 
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 Melena is passing dark coloured, tarry, foul smelling stools. Presence of 
melena indicates that the blood has been in the gastrointestinal tract for 
adequate time so as to be altered and converted to dark coloured stools. It is 
usually a minimum of 14 hours upto a period of 3 – 5 days. Melena requires a 
bleeding of around 50-60ml from the upper GI tract. 
 Hematochezia is passing bright red blood or maroon blood through rectum. 
This is usually a manifestation of  lower GI bleed but it can occur due to 
bleeding from a proximal source when the transit time is short. 
Epidemiology: 
In current day practice , UGIB is one among the common medical emergency 
encountered. An overall annual incidence of Acute upper GI bleeding in adults 
is approximately 100 per 100,000. It is more common among males  and 
markedly more common among the elderly. Its associated mortality rises with 
age. Lower GI bleeding is somewhat less common, with an annual incidence of 
approximately 20 per 100,000. This too, is more common among males and 
among the elderly. 
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Prevalence of UGIB in India and worldwide : 
Endoscopic
diagnosis
Deep 
Anand
et al
Anan
d et al
Odisha AAFP Rathod
et al
Jaka et al
Dehradun
North
India
AIIMS, 
North 
India
Odisha, 
India
Geogia,US Gujarat,
India
Tanzania
Varices 56.14% 45.4% 12.8% 6% 24% 51.3%
PUD 14.91% 30% 57.6% 62% 22% 25.0%
Erosive 
lesions
12.28% 8.5% 1.8% 8% 34% 15.8%
Mallory-
Weiss
8.77% 1.8% 4% -
Malignacy 4.38% 7.7% 2% 8%%
Esophagitis - 18% 1.7%%
Other 3.5% 2%
Normal 8% 3.3%
 
AAPF(1) Deep Anand(2)  Odisha(3) 
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Causes of upper GI bleed : 
 Peptic ulcer disease 
 Variceal bleeding 
 Gastroduodenal erosive lesions 
 Esophagitis 
 Mallory weiss tear 
 Neoplasm 
 Vascular lesions 
 
PEPTIC ULCER DISEASE: 
Peptic ulcer disease are  the most common causes of upper gastrointestinal 
bleeding . But epidemiological variation exists due to variation in food, lifestyle 
and economic pattern. Prevalence of PUD is ~ 12% in males and ~10 % in 
females. 
 Ulcer is the disruption in mucosal intergrity of stomach, duodenum.loss of 
mucosal surface more than  5 mm and depth upto submucosa defines the ulcer. 
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Pathophysiology : 
 The gastroduodenal system besides role in digestion , also performs 
immune defense and homeostasis of its own system. This is attained through 
gastrointestinal mucosa and epithelial and subepithelial components.  
 The gastroduodenal epithelium is exposed to constant insult to series of 
endogenous and exogenous substances; endogenous factors include 
hydrochloric acid, pepsin, pancreatic enzymes, bile salts and acids and 
exogenous substances include drugs, alcohol, microbes. The biologic system 
has its own defense to protect its mucosa from injury and the ability to repair 
any injury and the integrity is maintained by an intricate system. The protective 
mechanism includes, 
 i) Mucus bicarbonate phospholipid layer  - acts as a physiochemical barrier 
to the effects of  hydrogen ions and gastroduodenal enzymes. Mucus is 
produced from gastroduodenal surface epithelial cells, is primarily composed of 
95% of water and a mixture of phospholipids and glycoproteins. This mucus 
layer acts as a non stirred layer of water impeding movements of molecules and 
ions. Bicarbonate which is also secreted by the same gastroduodenal epithelial 
cells into the mucus forms a pH gradient, which is 1-2 at luminal surface and 6-
7 at the epithelial cell surface. 
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ii)Surface epithelial cells  - which has the following functions 
 Mucus production, 
 Maintenance of pH, 
 Epithelial cell ionic transporters, 
 Bicarbonate production, 
 Intracellular tight junctions, 
           Heat shock proteins – prevent protein denaturation and protect cells from  
increased temperature , cytotoxic agents and oxidative stress. 
          Restitution – process of migration of gastric epithelial cells to a nearby 
injury and restoration of the damaged region to normal occur in surface 
epithelium. This requires uninterrupted blood supply and optimal pH ( alkaline ) 
at that site of lesion. This regeneration  process requires presence of multiple 
growth factors and prostaglandins. 
iii)Prostaglandin role in homeostasis of GI mucosa: 
    Prostaglandins play a vital role in gastric epithelial defense and repair. It 
effects control over the synthesis and  release of bicarbonate secretion and 
mucus. It inhibit parietal cell secretion, and  maintains blood flow to the 
mucosal layer and epithelial cell restitution. 
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   Phospholipase A2 acts on the membrane phospholipids to form esterified 
arachidonic acid. Cyclo oxygenase ( COX) is the enzyme which acts on 
arachidonic acid to form prostaglandins. COX plays the crucial step in the 
prostaglandin synthesis. There are two forms of isoforms – COX1 and COX2 
each having its unique structure, distribution and function.COX1 is present in 
stomach, kidneys, platelet and endothelium; helps in maintaining the integrity of 
the organ in which it is expressed. COX2 is inducible by inflammation and 
expressed by macrophages,leukocytes, fibroblasts and synovial cells.  
The role of Nonsteroidal anti-inflammatory drugs in the pathology of peptic 
ulcer disease is understood from its effect on COX and in the production of 
prostaglandlin. This explains the etiological role of NSAIDs in the Peptic ulcer 
disease. 
 
Pathogenesis of PUD : 
Definite risk factors in the development of PUD are 
 Helicobacter pylori, 
 NSAIDs, 
                         -these two are the most frequently associated risk factors. 
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Additional risk factors include 
• chronic obstructive lung disease, 
• chronic renal insufficiency, 
• current tobacco use, 
• former tobacco use,  
• elderly age,  
• coronary heart disease, 
• former alcohol use,  
• African-American race 
• obesity and diabetes 
 
Duodenal ulcer : 
 Most common site of duodenal ulcer is the first part of the duodenum. 
Around 90%  of them are found within 3 cm of  pylorus. The size of the ulcer 
varies from  less than one centimetre to large as 6 cm. Ulcers of size 3 to 6cm 
are usually termed as giant ulcer. Ulcers have a sharply demarcated margin. 
Depth of the ulcer may reaches upto the muscularis propria. Histopathology 
features of the ulcer shows eosinophilic necrosis at the base with surrounding 
fibrosis. Duodenal ulcers are rarely malignant. 
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Fig.Normal duodenum         Duodenal ulcer 
 
 Increased average basal  and nocturnal gastric acid secretion and 
decreased bicarbonate secretion are the abnormalities associated with duodenal 
ulcer.  H.pylori infection has been considered as the contributory factor to the 
foresaid abnormalities. 
Gastric ulcer : 
 Gastric ulcers unlike that of duodenal ulcer can represent malignancy and 
biopsy should be done. Benign gastric ulcers are most often found distal to the 
junction between the antrum and the acid secretory mucosa and  rarely occur  in 
the gastric fundus.  
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Fig: Normal stomach     Gastric ulcer 
 
Histologically gastric and duodenal ulcers show similar features and that is the 
distribution and morphology which differentiates them . 
 H. Pylori infection is associated with benign gastric ulcer and shows antral 
gastritis.  But gastric ulcers due to NSAIDS are not associated with coexixting 
gastritis. They may exhibit  evidence of a chemical gastropathy - typified by 
foveolar hyperplasia, edema of the lamina propria, and epithelial regeneration . 
Extension of smooth-muscle fibers into the upper portions of the mucosa may 
also occur(4). 
Gastric ulcers are associated with normal or decreased acid production .Mucosal 
defense may also be impaired. Gastric ulcers have certain characteristics based 
on their location. 
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Gastric ulcer classification  and characteristics : 
GASTRIC ULCER SITE ACID PRODUCTION 
TYPE I Body of stomach Low 
TYPE II Antrum Low to normal 
TYPE III Within 3cm of pylorus Normal or High 
TYPE IV Cardia  Low  
 
 
Helicobacter pylori : 
H.pylori is a gram-negative microaerophilic rod with  multiple sheathed 
flagella. It usually habitats in the deeper part of the mucosal layer and doesnot 
invade the cell under normal acidic environment. But it is capable of  living 
within the aggressive environment of the stomach.  Initially, H. Pylori lives in 
the antrum but move towards  the more proximal part of the stomach.Under 
adverse condition, the organism transforms into a dormant state to survive. 
The protective effect of acidic pH is tackled with the ability of the oraganism to 
change its surrounding into alkaline pH. This is done by the urease enzyme 
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activity of H.pylori which produce ammonia from urea and makes its 
environment alkaline. 
The H.pylori infection differs among population and it depends on the quality of 
life of that region. Factors influencing infection with H.pylori are  habitat in a 
developing nation i)congestion, ii)unhygienic living conditions,iii)contaminated 
water and food, and iv)exposure to gastric contents infected with H.pylori 
Human to human transmission occurs through oral-oral or  faecal- oral route. 
NSAIDs: 
Side effects of nausea and dyspepsia occurs in around  
50–60% and peptic ulceration occurs in ~15–30% of individuals taking NSAIDs 
regularly. Complications of PUD occur in about ~1.5% individuals among 
them. 
The role of NSAIDs in the pathology of peptic ulcer disease is 
understood from its effect on COX and in the production of prostaglandlin. The 
beneficial therapeutic effect of NSAIDs occur due its inhibitory effect on COX2 
and the toxicity is due to its inhibitory effect on COX1 isoform leading to 
mucosal ulceration and renal dysfunction. COX2 selective inhibitors have 
advantage over nonselective NSAIDs in minimising the tocic effects on 
mucosa. But certain drugs cause adverse effects on cardiovascular system and 
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myocardial infarction.This explains the etiological role of NSAIDs in the Peptic 
ulcer disease. 
Most of the patients who develop serious NSAIDs related complications 
do not experience preceeding dyspeptic symptoms. In this regard, NSAIDs 
related complication should be borne in mind in asymptomatic patients with 
chronic drug intake. Concomitant  H. pylori infection increases the risk of PUD-
associated GI bleeding in chronic users of low- dose aspirin. Established risk 
factors for NSAIDs induced PUD include advanced age, history of ulcer, 
concomitant use of glucocorticoids, high-dose NSAIDs, concomitant use of 
anticoagulants, clopidogrel, multisystem disease or organ failure, cigarette 
smoking, and alcohol consumption. 
 
Smoking : 
 Smoking is a risk factor for peptic ulcer disease and following 
mechanisms has been ascribed. 
Decreased bicarbonate production 
Altered gastric emptying, 
Generation of noxious mucosal free radicals. 
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VARICES : 
  Varices are important cause for upper gastrointestinal bleeding. Varices 
reflects the presence of portal hypertension. Portal hypertension is defined as 
elevated hepatic venous portal gradient more than 5 mmHg.  
 Gastroesophageal varices develop in  5–15% of cirrhotics per year.Most 
of the cirrhotic patients will  develop gastroesophageal varices with time. The 
apperance of gastroesophageal varices shows relation  with the severity of liver 
disease. Varices in present in 40 percent of Cirrhotics with child pugh score A , 
and 85 percent of child pugh score C patients(5).  
Anatomy and physiology of Portal venous system : 
 The portal vein is formed by the confluence of the superior mesenteric 
and splenic veins.  
Spleenic vein drains blood from the spleen, fundus of stomach and part of 
the pancreas. Inferior mesenteric vein drains blood from the large intestine -
transverse colon,descending colon and rectum – superior two thirds usually 
joins the spleenic vein 
Superior mesenteric veins drain blood from  small intestine, large 
intestine, stomach , pancreas and appendix. 
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Portal hypertension leads to two major complications – variceal hemorrhage and 
ascites. 
Pathophysiology of varices formation : 
Anatomically collaterals usually exists between the portal venous system 
and the systemic venous system at certain anatomic locations. Blood flows from 
the systemic circulation into the portal system. 
Two pathogenesis contributing to portal hypertension are  
• Increased resistance to portal venous flow due to extrahepatic 
obstruction or intrahepatic resistance due to cirrhosis and regenerative 
nodules. 
Fig.Normal portal venous flow and 
pressure 
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• Increased splanchic blood flow due to vasodilation of splanchic 
circulation. 
 
Fig.Collaterals formation at esophagus in portal hypertension 
When portal hypertension develops, the resistance in the portal vessels 
pressure raises more than  that of the systemic system,and causes reversal of 
flow . This is transmitted to the portosystemic junctions and the collaterals 
become dilated and distended 
Angiogenesis and  new blood vessel formation also occur with an effort to 
increase collataeral bed to decompress the portal hypertension but when the 
collateral is unable to withstand the pressure, dilation of vessels occur.further 
compromise leads to complication of rupture and bleeding. 
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Varices should be kept in mind while treating all patients with clinical picture of 
liver cell failure. Once diagnosis of cirrhosis is made, the patient should be 
subjected to endoscopy to rule out varices and appropriate management should 
be done. When absent, periodic review and yearly endoscopy should be done 
Anatomical location of varices in UGIB:  
Causes of portal hypertension  
1.Prehepatic causes 
Portal vein obstruction  
 Idiopathic  
 Cirrhosis  
 Infection 
 Pancreatitis  
Fig.Direction of flow and 
pressure in intrahepatic portal 
venous obstruction 
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 Abdominal trauma. 
 Coagulation disorders  
- polycythemia vera,  
- essential thrombocytosis, 
-  deficiencies in protein C, 
-  protein S deficiency, 
-  antithrombin 3 deficiency, 
-  factor V Leiden 
Spleenic vein thrombosis 
Massive spleenomegaly – Banti’s syndrome 
 
2.Hepatic causes : 
 Presinusoidal 
- Schistosomiasis 
- Congenital hepatic fibrosis 
Sinusoidal 
- Cirrhosis of any etiology 
- Alcoholic hepatitis 
Postsinusoidal 
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Hepatic sinusoidal obstruction  
3.Post hepatic causes 
- Budd-Chiari syndrome 
- Inferior vena caval webs 
- Cardiac causes 
- Restrictive cardiomyopathy 
- Constrictive pericarditis 
- Severe congestive heart failure 
    
 
 Fig.Causes of portal hypertension  
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Esophageal varices: 
Gastroesophageal collateral bed  is the common site of  variceal 
formation and bleeding. When the HVPG exceeds 10 mm Hg, esophageal 
varices develops. In esophagus, the varices along the lower 2 to 3 cm 
submucosa lies very superficial, have fragile thin wall and so why bleeding 
usually occurs at this site. These vessels do not communicate with the 
periesophageal veins and therefore cannot easily be decompressed(8)*.  
 
 
Esophageal varices may be small – less than 5mm or large –greater than 5 
mm.Small varices progress with time into large varices. The predictors of first 
bleeding include the size of varices, severity of cirrhosis (Child B or C), 
variceal pressure (>12 mm Hg), and the endoscopic presence of red wale 
marks(5) 
Fig:Esophagus - 
subcutaneous venous plexus 
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Fig: Probability of bleeding with relation to size of varices and Child pugh score 
Fig:Endoscopy Grading of Esophageal varices 
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CHILD PUGH Score: (6) 
Parameter           Score 1    Score  2  Score  3 
Ascites   None Mild/Moderate Tense 
Hepatic encephalopathy None Grade 1-2 Grade 3-4 
Bilirubin (mg/dL) <2 2-3 >3 
Albumin g/L (g/dL) >3.5 2.8-3.5 <2.8 
PT (Sec over control)or <4 4-6 >6 
INR   <1.7 1.7-2.3 >2.3 
 
Childpugh A 5-6;  B 7-9;  C 10-15 
Gastric varices : 
Gastric varices occur less common than esophageal varices around 5 – 30% ( 5 ) 
of portal hypertension. Bleeding occurs in about one-fourth of them. Gastric 
varices can occur in isolation or as extension of esophageal varices. 
Gastic varices are classified according to the site and association with 
esophageal varices.(Sarrin et al.) 
Gastroesophageal varices[ 2]  
 Type 1 varices - extend along the lesser curvature. 
 Type 2 varices - extend along the fundus.  They are longer 
and more tortuous than GOV1 
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Isolated Gastric varices [ 2 ] :  
 Type 1 - fundus and tend to be tortuous and complex 
 Type 2 - body, antrum, or around the pylorus.  
Isolated gastric varices at fundus  may occur due to spleenic vein thrombosis 
and should be ruled out. 
Ectopic varices: 
 Varices may occur anywhere in the gastrointestinal tract.when present in 
GI tract other than esophagus and stomach, they are termed as ectopic varices. 
They are difficult to identify and continue be a concealed source of bleeding 
.once identified the appropriate treatment modalities are not well established. 
Management  
Endoscopy has evolved as the principal diagnostic as well as therapeutic tool in 
management of upper gastrointestinal bleed. Endoscopy era has made to review 
the etiology of upper GI bleed as the most common cause varies with region. It 
helps in identifying individuals and categorising them accordingly to be 
managed by primary prophylaxis in newly diagnosed cirrhotic or need for 
endoscopic intervention or surgery. 
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Fig: Management of Acute variceal bleed 
Hematemesis or Melena 
Phamacotherapy – Vasoactive drugs 
Diagnostic Endoscopy 
Active Variceal Bleeding 
Sclerotherapy / Banding 
Baloon Tamponade 
for 24hours 
Secondary 
prevention 
Pharmacotherapy          
 
Repeat Therapeutic endoscopy 
Follow up 5 days 
      GLUE Injection / TIPS /  
      Transplant Consideration 
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Patients presenting with upper GI bleed should be stabilised before 
endoscopic intervention. This include insertion of nasogastric tube to confirm as 
well as quantify the amount of blood loss, maintaing intravascular volume by 
crystalloids, colloids. Blood transfusion is done when patient has anaemia.once 
the patient was stabilised,endoscopy is planned as early possible preferentially 
within 24 hours. Though advancement in technique and treatment has occurred, 
the availability of the endoscopy facility determines the timing of endoscopy.  
 
MALLORY-WEISS tears : 
Mallory – weiss tear is a nontransmural tear at the gastroesophageal 
junction that is caused by vomiting, retching, or vigorous coughing. It is one 
among a common cause of upper gastrointestinal bleeding. Most patients 
present with hematemesis but antecedent vomiting is  not always evident as that 
of expected. Bleeding usually stops spontaneously, but protracted bleeding may 
occur. The prolonged bleeding is managed by injection of local epinephrine or 
cauterization therapy, endoscopic clipping, or angiographic embolization. 
Surgery is rarely needed. 
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Erosive Gastroduodenal disease : 
Acute erosive gastric mucosal lesions or frank ulceration with bleeding can be 
precipitated by any form of stress. This includes sepsis, burns, severe injury, 
shock, head injury etc and manifest usually 48-72 hours after the insult.  
 
Fig: Erosive gastric mucosal lesions 
 
These stress induced ulcers are most commonly found in the acid-
producing   portions of the stomach – body and fundus of stomach. They 
manifestation usually as abdominal discomfort associated with acute 
gastrointestinal bleeding. The severity of bleeding is minimal but may be life 
threatening at times. Patient under  mechanical ventilation and underlying 
coagulopathy are risk factors for bleeding. 
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Esophagitis : 
 Esophagitis is the inflammation of esophagus due to various etiologies.  
                                
Normal esophagus             Esophagitis  
 
Lax lower esophageal sphincter leads to gastroesophageal reflux disease which 
is the common cause. Risk factors include Alcohol consumption, smoking, 
medication – NSAIDs. Pill esophagitis, eosiniophilic esophagitis, infections due 
to H.pylori, Candidiasis, Radiation and corrosive induced lesions are other 
causes. 
  
Vascular Lesions : 
Vascular ectasias are flat mucosal vascular anomalies that usually causes 
slow intestinal blood loss. This occurs as either in a sporadic fashion or in a 
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well-defined pattern of distribution. e.g., gastric antral vascular ectasia -  GAVE 
or “watermelon stomach” .  
They are often responsive to local endoscopic ablative therapy, such as argon 
plasma coagulation. 
Patients with diffuse ectasias associated with chronic renal failure and with 
hereditary hemorrhagic telangiectasi, the chances of recurrent bleed occurs  
despite endoscopic treatment of easily accessible lesions by conventional 
endoscopy. These patients may benefit from deep enteroscopy with endoscopic 
therapy, pharmacologic treatment with octreotide or estrogen/progesterone 
therapy, or intraoperative enteroscopy. 
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Laboratory investigations in Acute GI bleed: 
Laboratory data assists in the management of  acute GI bleed. 
Haemoglobin does not fall rapidly unless there is severe bleed. Fall in  
Hematocrit helps in assessment of severity of blood loss. The change in 
hematocrit occurs after about 24 hours and the delay is due to proportionate loss 
of plasma along with erythrocytes. The subsequent fall in dilution of hematocrit 
is due to movement of extravascular fluid into vascular compartment. This may 
be further altered by fluid resuscitation. 
          Thus significance of a single hematocrit value cannot be inferred unless a 
recent previous report is available. Series of hematocrit values are done to 
monitor the status of patient and this should be correlated clinically and 
according to the fluid administered. More accurate assessment of volume status 
can be done with central intravenous catheter and applied when it is highly 
useful in patients with co existing renal or cardiac failure. 
Investigations done towards etiology includes monitoring of liver and renal 
parameters, coagulation profile, white blood cell count, platelet count. Anaemia 
is normocytic normochromic in acute GI bleed and becomes microcytic in 
chronic loss due to iron deficiency. Leukocytosis occur due to stress, but 
infection should be ruled out. Thrombocytopenia reflects hypersplenism due to 
portal hypertension. Thrombocytopenia is an early indicator of onset of portal 
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hypertension. Renal parameters especially urea is elevated as a result of 
hypovolemia and also due to the absorption of denatured proteins in the blood 
that has passed through the intestine.Elevated  urea creatinine ratio indicates the 
prerenal azotemia due to hypovolemia.  
 
Management of Upper GI Bleed : 
General measures : 
Nasogastric tube  : 
Nasogastric aspiration with saline lavage should be done routinely to 
detect the presence of intragastric blood, to assess the bleed quantitatively, and 
clear the gastric contents to prevent aspiration as well a prerequisite in case of 
emergency endoscopy management.. A gross bloody aspirate confirms a UGIB, 
unless trauma occurs during nasogastric tube insertion. Bright red blood 
suggests currently active bleeding, whereas coffee grounds suggest recently 
active bleeding. Absence of bloody aspirate doesnot exclude upper GI bleed, 
since gastric contents may have emptied during the transit period. 
When nasogastric aspiration is impossible prior endoscopy, erythromycin 
. Intravenous infusion of 250 mg ~ 30 min helps in rapid gastric 
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emptying.emptying gastric contents helps in better endoscopic visualisation and 
avoids repeating the procedure. 
Ice cold saline/water instillation through ryles tube causes local 
vasoconstriction and reduces bleeding temporarily .  
Blood transfusion : 
Blood transfusion, fresh frozen plasma are transfused appropriately  
Pharmacotherapy : 
 NonVariceal Bleed : 
 Protein pump inhibitors patenteral 
 Antibiotics 
 Anti – H.Pylori regime 
 Variceal Bleed :   
 Proton pump inhibitors 
 Prophylactic Antibiotics –parenteral 
 Vasoactive drugs  
-  Vasopressin / Terlipressin 
- Stomatostatin and analogues 
-  
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Proton pump inhibitors : 
 Proton pump inhibitors acts by inhiting gastric proton 
pump(H+K+ATPase).These are prodrugs that require acidic medium for 
activation. Once absorbed into circulation these drugs reach the parietal cells of 
stomach and gets attached to canaliculi.The binding to canaliculi is irreversible 
and makes the duration of action longer until new pumps are formed.Since these 
drugs block the pumps, they are more effective.  
These patients requiring immediate acid suppression are treated with parenteral 
pantoprazole or lansoprazole. A single intravenous bolus of  80 mg of 
pantoprazole inhibits acid production by 80% to 90% within an hour  and this 
inhibition persists for long duration, permitting once daily dosing. 
Since most causes of upper GI bleed are associated with acid secreting 
abnormalities and mucosal injury like gastric ulcer, duodenal ulcer, esophagitis, 
erosive mucosal lesions proton pump inhibitors blocks the common 
pathogenesis involved. This reduces the severity and further active bleed. 
Vasoactive drugs : 
  Vasopressin and terlipressin causes vasoconstriction of splanchic 
arterioles and decreases the in flow of blood and lowers portal pressure. 
Vasoconstriction at other organs may cause colicky or myocardial ischemia. 
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Dose of vasopressin is 2 mg i.v. QID for 48 h.Further dose of 1 mg every 4 – 6 
h  may be continued for a further 3 days.  
Stomatostatin and octreotide  decreases blood flow to the gastrointestinal 
tract andt has been used to treat bleeding esophageal varices, peptic ulcers, and 
postprandial orthostatic hypotension. Standardly used to reduce the risk of 
bleeding from esophageal varices because it inhibits mesenteric vasodilatation 
induced by glucagon. 
 Stomatostatin 250microgram iv infusion followed by 6mg/kg infusion 
over 24hours. Treatment is initiated in suspected cases of variceal bleed, 
previous history of varices, clinical evidence of liver disease  
and elevated biochemical parameters.  
 Octreotide  is administered at dose of 50 -100 microgram / hour infusion.  
Sengstaken-Blakemore tube : 
 Esophageal balloon compression causes occlusion of submucosal 
vessels and stops bleeding. Sengstaken-Blakemore tube consists of esophageal 
and gastric balloon. The gastric balloon is inflated first to place the tube in 
position. The pressure applied at esophageal balloon shoulb be greater than the 
expected portal pressure. Once both balloons are inflated slight traction is 
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applied to avoid the tube from slipping into stomach. After 12 hours esophageal 
balloon is deflated and check for bleeding. If recurs reinflate till 24 hours.  
  
 
 
This procedure used as a temporary method to control bleeding, during 
transportation to referral center or till dfinite therapy is available. Compression 
should not be given more than 24hours.  
ENDOSCOPY : 
 It is the initial test in the evaluation of Upper gastrointestinal bleed. 
Upper GI Endoscopy is the technique through which gut lumen is visualised 
through a scope passed through oral cavity.The modern era of endoscopy began 
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with the development of fibreoptic instruments in the 1960s. For most purposes 
these are being supplanted by video chip endoscopes in the 1990s(8) 
 It is most essential tool in evaluation of  suspected peptic ulcer disease, 
neoplasm, malignancy, esophagitis, unexplained anemia, malabsorption. Patient 
presenting with chronic symptoms of dyspepsia, vomiting, unintentional weight 
loss, anaemia, malabsorption are benefitted by endoscopic evaluation. Scopy 
besides identifying the lesion also provides the opportunity to confirm the 
suspected lesion by access to biopsy in the first sitting when present. 
 Endoscopy offers the advantage of therapeutic intervention in single 
sitting. The endoscopic  techniques have evolved over time with developing 
technologies and include sclerotherapy,injection of adrenaline, variceal ligature 
banding, glue injection,endoscopic clippings, electrocautery and argonplasma 
anticoagulation. 
Instrument [1] : 
They basically consists of  i)control head  ii)flexible shaft. The shaft is 
designed technically in such a way that it’s tip can be manipulated with controls 
at the head. Umbilical cord is the part through which light source reaches the 
head. It serves as a link through wich external light, air, suction and water is 
connected to the control head. The suction channel is used for the passage of 
diagnostic tools (e.g. biopsy forceps) and therapeutic devices  
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Fibrooptic instruments : 
The fibro-optic cable bundle  is 2–3·mm in diameter and contains 
20·000–40·000 fine glass fibres, each close to 10·µm in diameter.  Each fibre 
carries the light focussed on it to the other end of the cable by using the property 
of repeated internal reflections of light. The light transmitted to other end is 
processed to form the image based upon the spatial orientation of the individual 
fibres  throughout the shaft. Leakage of fibre from each fibre is achieved by 
coating each fibre with glass of lower optical density. Thus the flexible 
endoscopy is designed technically that it can transmit image even when it is 
flexed to make a knot. 
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Videoendoscope[1] : 
Videoendoscope uses a chip (charged couple device -CCD)mounted at 
the tip of the scope which absorbs light from the image. Instead of fibreopticals, 
to and fro wiring connect the chip to the control head by way of electronics. The  
site of the ocular lens in a fibre-endoscope is replaced by controls and knobs in 
videoendoscope to focus on a lesion. This allow the scopist to have a view at a 
screen and the instrument can be manipulated via the control head. 
Videoendoscopes offer the advantage the gut can be visualised by everyone in 
the room, which is restricted only to the scopist in case of fibroscope. It also 
provides better clarity in the printed copy of the obtained image. 
Light source – is obtained from an external high beam source which is 
transmitted through the umbilical cord to the scope. 
Instrument control : 
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The instrument tip is manoeuvred with help of wires attached just beneath the 
tip, which passes through whole length of the scope. These wires are controlled 
with provisions at the control head. The tip can be moved right, left, up or down 
and can be fixed at any angulation. This causes no damage to the instrument.   
 
 
In addition to the visual imaging, the diagnostic and therapeutic 
manoeuvres are achieved via the provisions for instrumentation through the 
shaft. Instrument accessories are made to pass through the shaft via ports at the 
control end, to the  
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  field of view.  
 
The following flexible instruments are passed through, 
 Biopsy forceps 
 Cytology brush 
 Diathermy 
 Sclerotherapy needle 
           Detachable snare 
 
 
52 
 
Irrigation system with suctioning facilitates flushing the lesion, identifying 
oozing point. Air can be insufflated through the shaft. The water and air supply 
is obtained from external source via the umbilical cord to control head. 
Upper GI scopy passes through esophagus, stomach, upto first and 
second part of duodenum. It is the initial test in the evaluation of suspected 
peptic ulcer disease, neoplasm, malignancy, esophagitis, unexplained anemia, 
malabsorption. Patient presenting with chronic symptoms of dyspepsia, 
vomiting, unintentional weight loss, anaemia, malabsorption are benefitted by 
endoscopic evaluation. Scopy besides identifying the lesion also provides the 
opportunity to confirm the suspected lesion by access to biopsy in the first 
sitting when present. 
 
Indication for upper GI scopy in suspected UGIB : 
 Hematemesis 
 Melena 
 Hematochezia 
 Anemia  
 Suspected Malignancy 
 Peptic ulcer disease 
 Unintentional weight loss 
Dyspepsia with signs of organic disease 
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Indications for endoscopic therapy(9): 
• Active spurting or oozing bleeding or a non-bleeding visible vessel 
• Adherent clot resistant to vigorous irrigation 
 Ulcer with a clean base or a flat pigmented spot needs no endoscopic 
intervention. 
Treatment with proton pump inhibitors should be continued with via 
parenteral route for patients who have stigmata of recent hemorrhage like 
oozing from vessel, adherent clot, non bleeding visible vessel. oral dosage of 
pantaprazole or other PPIs should be continued for findings of clean base ulcer 
or pigmented spots. 
Repeat procedure is done when there is recuuence of bleed after initial 
endoscopic management. When further episodes occur surgery or arterial 
embolisation should be considered. 
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Stigmata of hemorrhage in ulcer : 
FORREST CLASSIFICATION of Stigmata of Hemorrhage 
Stigmata  
of hemorrhage 
Forrest 
classification   Prevalence 
Active spurting bleed IA   12% 
Active oozing bleed IB     
Non-bleeding visible 
vessel IIA   8% 
Adherent clot IIB   8% 
Flat pigmented spot IIC   16% 
Clean Base III   55% 
 
ROCKALL SCORE : 
   For scoring 0, 1, or 2 rebleeding occurs in less than 5% of patients and 
mortality is virtually zero whether rebleeding occurs or not. The scoring system 
can be used to identify the one quarter of patients who are at negligible risk of 
dying but this can only be done only after confirming the diagnosis by 
endoscopy for stigmata of recent haemorrhage. An admission Rockall score of 
zero is often cited as identifying low risk patients, Patients with a Rockall score 
of ≤ 2 are generally accepted as being at low-risk of poor outcome, As with all 
true emergencies, the traditional triad of medical history, physical examination, 
and diagnosis often must be accomplished simultaneously with resuscitation 
and stabilization.  Rebleeding has its most profound influence on mortality in 
the middle risk groups that score 3 or 4, when it is associated with an 
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approximately fivefold increase in mortality. In risk groups 5 to 7 rebleeding is 
associated with an approximately threefold increase in mortality and for risk 
group 8, a twofold increase(10) Rockall score also serves as prognosis both 
before and after a definitive endoscopic diagnosis. It helps in prioritising 
patients to be admitted to undergo endoscopy where there is limited availability 
of facilities and human resource. 
Based on the score, it helps whether to treat patient as inpatient or period of stay 
based on the stigmata of recent hemorrhage. 
 
GLASGOW BLATCHFORD SCORE(11) : 
           SCORE     RISK STRATIFICATION  
             0   Low risk 
 Reasonable to manage as out patient 
          1 – 5  Increased risk for intervention 
 Inpatient treatment is recommended 
 Most patients recover without significant 
intervention 
           >5 High risk for intervention 
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GBS of zero has been reported to have > 99% sensitivity in identification 
of those who do not require intervention, rebleed or die in studies from Hong 
Kong (China)[30], United States[31], Japan[38], Taiwan (China)[27] and 
United Kingdom[18,23,25,28].  low risk patients suitable for out-patient 
management to those with GBS ≤ 1 or ≤ 2, but safety of this approach requires 
further study 
 
Endoscopic procedures 
 
Endoscopic injection sclerotherapy (EST) [2] 
More than half a century after it was introduced by Crafoord and Frenckner 
[20], EST remains the primary treatment for bleeding esophagogastric varices in 
many parts of the world. It is used both in the control of acute bleeding and in 
elective obliteration of varices. Autopsy studies indicate that venous 
thrombosis, mucosal ulceration and acute inflammatory reactions can be found 
in the injection site as early as 2 days after sclerotherapy (13)  
1.Intravariceal injection -  Injections may be injected into the veins or 
2.Paravariceal injection  – injected into esophageal wall adjacent to the 
varices. 
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The intravesical injection is usually preferred. Sclerosant should be injected into 
each variceal column starting from the lower esophageal gastric junction 
upwards to the mid esophagus. 
Sclerosing agents are two types, 
 i) fatty acids           ii)dehydrating agents  
Fatty acids- e.g. sodium morrhuate, ethanolamine oleate, polidocanol or 
Dehydrating agents - e.g. sodium tetradecyl sulfate, ethanol, hypertonic glucose, 
and phenol. 
 1–2 ml  are injected into each column at esophagogastric junction. A total 
volume of 20 ml can be injected at each session [2] 
Post sclerotherapy : 
Patients are observed for several hours and if no bleeding occurs, oral 
intake is resumed. Acid suppressive therapy and mucosal protectives are used to 
prevent excessive ulceration of esophagus. Patient is reviewed biweekly or 
more for futher sittings to make the remnant varices sclerosed.   
Endoscopic variceal ligation : 
Endoscopic variceal ligation was first introduced by Stiegmann and Goff 
in 1986 [28,29]. Variceal banding involves strangulation of varices by elastic 
circular ligatures. These ligatures are mounted on tip of endoscope. The varix is 
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sucked into the scope completely and the ligature is released, such that it 
constricts the neck of the scucked in part. Banding should begin distally and 
moved spirally towards proximal esophagus since the ligated varix obstructs 
vision and passage of the scope.This approach prevents the chance of 
obstruction of food passing through esophagus in later period. 
Multi fire devices has overtook the initial single fire devices avoiding the 
need for passing the scope multiple times in case of multiple varices. 
EVL obliterates varices by causing necrosis of mucosa and submucosa of 
the esophageal wall. After few sitting of EVL, the varices become small and the 
esophagus is scarred. 
Demerits : 
Early recurrence of varices is a problem associated with EVL. 
Esophageal varices may recur within months after treatment and it is more 
frequent in EVL. Recurrence is considered due to persistence of perforating 
veins in esophagus.These veins are considered as the determinant factor for 
recurrence; are not occluded by EVL.  In almost all studies comparing the long-
term effects of EST vs. EVL, recurrence of esophageal varices were found more 
frequently in the EVL-treated patients (30–48%) compared to the EST-treated 
patients (8–30%)(14)(15) 
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 Rebleeding from gastric varices may be more common among those 
treated by EST than by EVL (37% vs. 8%)[2] The overall survival rates are 
similar in both treatment modalities and it is determined by hepatic reserve 
rather than by the method of endoscopic hemostasis. 
Cyanoacrylate : 
Endoscopic injection of the varices with N-butyl-2-cyanoacrylate was 
first introduced by Soehendra in 1995(16). The tissue adhesive coagulates 
almost instantaneously when in contact with blood. It is mixed with lipoidal 
solution to prevent adhesion in the scope channel. The procedure is carried out 
under fluoroscopy surveillance to ensure injection into the dilated varices. 
The injected submucosal vessels become hard and the bleeding is stopped. Later 
the vein sloughs off and fall.Cyanoacrylate is very effective in controlling active 
spuring variceal haemorrhage and achieve acute hemostasis. 
It is the preferred treatment modality in gastric varices where banding is not 
possible. 
Complications : 
Esophageal ulceration,Stricture,Spasm,Septic and organ emboli in 
cyanoacrylate,Peritionitis,Bacteremia  
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Detachable snare : 
 Varices is sucked into the scope and a detechable snare is released to 
enclose it. The varices then appear as a polyp with a string attached to its base. 
The varices gets thrombosed and falls off. Advantage is does not require 
multiple sitting, but needs technical expertise. 
Treatment of H.pylori : 
Triple regimen  
 
 
 
 
 
 
 
 
 
 
Quadraple regimen : 
 
 
 
 
     
 
PPI  tablets bd 
       Clarithromycin 500mg bd 
       Amoxicillin 1 g bd 
 
           PPI  tablets bd 
       Clarithromycin 500mg bd 
       Metronidazole 500mg bd 
  
 Omeprazole (lansoprazole)  20 mg bid (30 mg bid) 
 Tetracycline 500 mg tid 
 Metronidazole 500 mg tid 
 Bismuth salicylate two tab qid 
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Study method and material 
 
Study population: 
    This study was  conducted among 100 patients who presented with 
upper GI bleed  and underwent upper GI scopy at Government Rajaji 
Hospital,  Madurai, during the study period. 
Inclusion criteria: 
      1.Patients undergoing upper GI endoscopy for evaluation of upper GI 
bleed comprising hematemesis or/and melena.  
      2.Age > 14years  
      3.Gender: Both Male and Female 
Exclusion criteria: 
             Age < 14 years  
    Known case of bleeding diathesis 
    Patients who satisfy inclusion criteria and are hemodynamically 
unstable to undergo upper gastrointestinal scopy 
Design of study:    
       Descriptive Observational  study  
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Period  of study:    
       Six months January 2016 to July 2016 
Ethical clearance:  
Necessary ethical clearance was obtained from ethical committee ,GRH , 
Madurai. 
Consent: Individual written and informed consent. 
Analysis: Statistical analysis. 
Conflict of interest: Nil 
 
Data collection: 
•  Patients who presented with  upper GI bleed were assessed clinically and 
evaluated . Supportive measures and treatment were initiated and once 
patient are hemodynamically stable, endoscopy is done after obtaining 
consent. Clinical parameters,  Laboratory values, Endoscopic finding are 
assessed and documented and appropriate therapy was provided. Patients 
were observed post procedure and treated as inpatient or outpatient based 
on their health status. Follow up and review was done regularly.  
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Statistical analysis : 
 
 The obtained data were recorded and analysed. Statistical analysis 
of  frequencies, percentage, mean, chi-square test were done using 
computing system with the recent available tool – IBM SPSS statistics 
version 21. Statistical values were interpreted and significance recorded 
and results were reported. 
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 Results and analysis of the study 
  
   
Table 1: Age distribution among study population: 
 
Age in years Frequency Percentage % 
<20 2 2 
21-30 12 12 
31-40 23 23 
41-50 29 29 
51-60 25 25 
61-70 7 7 
>70 2 2 
Total 100 100 
 
In this Study, total samples of 100 patients, most of them falls under 4th 
and 5th decade. Age 40 -50 years comprises 29%; 50-60 years comprises 25% 
and 30-40years comprise 23%; 20-30 years comprises 12%. 
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Table2 : Gender distribution among the study population : 
 
Sex Frequency Percent 
 
Male 72 72.0 
Female 28 28.0 
Total 100 100.0 
  
         Sex distribution shows  more of males contributing 72% and           
females 28%. This reflects more prevalence of upper GI bleed in males. 
 
72%
28%
Gender distribution among study population 
Male Female
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Table3 Distribution of  symptom among  study population : 
 
Symptoms  Frequency Percentage 
Hematemesis alone 48 48 
Melena alone 19 19 
Hematemesis and melena 33 33 
Total 100 100 
 
Hematemesis alone occurred in 48% of patients. 
Melena alone occurred in 19% of patients. 
Both Hematemesis and melena occurred in 33% of patients 
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Table4 Distribution of Endoscopic diagnosis among study population : 
 
Endoscopic 
Diagnosis 
Frequency Percentage        
% 
Varices 36 36 
PUD 25 25 
Erosive 
gastroduodenal 
disease 
10 10 
Esophagitis 3 3 
Mallory-Weiss 
tears 
6 6 
Neoplasm 7 7 
Vascular 
lesions 
2 2 
No identifiable 
lesion 
11 11 
Total 100 100 
 
 Analysing the etiology of upper GI bleed in this study revealed 
Variceal bleeding as the most common cause in our hospital, which is a tertiary 
referral center in this region. Variceal bleeding occurred in 36% of patients. Next 
to varices is the peptic ulcer disease which constituted 25% . Other etiological 
findings in decreasing order is as Erosive gastroduodenal disease 10%, Neoplasm 
7%,Mallory-Weiss tear 6%, Esophagitis 3%, vascular ectasia 2%. No identifiable 
lesions was found in 11% of the patients enrolled in the study.  
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Table5 Distribution of risk factors among study population : 
  
Risk factors Frequency Percentage% 
Alcohol 44 44% 
NSAIDS 15 15% 
Antiplatelets 4 4% 
Smoking 11 11% 
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 Alcohol : 
           Alcohol intake was found to be in 44% of patients and absent in 56% of 
patients. Regarding alcohol and gender relation, alcohol intake was found only 
among males who were enrolled in this study. 
 
NSAIDs : 
         NSAIDs intake was found in 15% of patients enrolled in this study.  
 
Antiplatelet : 
         Antiplatelet drug intake was recorded in 4% of study population. 
 
Smoking : 
      History of smoking was recorded in 11% of  study population and 
distributed only among male gender. 
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Table6 Distribution of Co-morbidity among study population : 
 
Co-
morbidity 
Frequency Percentage 
% 
CKD 7 7 
IHD 9 9 
CCF 3 3 
 
               Among the study population, co-existing morbidities were found in 
19% of patients. Chronic kidney disease was found in 7%, Ischemic heart 
disease in 9% and Heart failure in 3% of patients. 
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Table7 Preexisting CLD among variceal patients in study population 
Preexisting CLD Frequency Percentage% 
Present 
21 21 
Absent 
79 79 
Total 
100 100 
 
            Information regarding pre-existing liver disease was recorded from 
history and previous records and found to be in 21% of the study population. 
 
Upper GI bleed as initial presentation in liver disease among study 
population : 
21
15
Distribution  of variceal bleed as initial presentation in CLD among 
study population
Preexisting CLD
New cases
No. of patients with Varices among study  population
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Table8 Child pugh score among variceal patients in study population  
Child pugh score Frequency Percentage % 
A 15 15 
B 16 16 
C 5 5 
Total 100 100 
 
 Severity of liver disease was assessed with Child pugh score in 
applicable patients. 64 patients of study population are not applicable. Among 
the rest  36 patients(36%) of patients, Child pugh score A was found in 15 
patients(41.6%)),score B in 16(44.4%) and score C in 5(13.8%) . 
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Table9 
 Relation between Childpugh score and mortality in study population 
    Patients 
             
Mortality   P value 
    Frequency Frequency Percentage %   
Childpugh A 15 0 0   
  B 16 3 18% 0.007* 
  C 5 3 60%   
*Statistically significant 
 
 
 
 
 
Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 
9.810a 2 .007 
Likelihood Ratio 10.268 2 .006 
Linear-by-Linear 
Association 8.852 1 .003 
N of Valid Cases 36     
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Table10 Distribution of  Rockall score in study population: 
Rockall score Frequency Percentage % 
0 20 20 
1 – 3 38 38.00% 
4 – 7 32 32.00% 
>7 10 10.00% 
Total 100 100 
 
          Risk stratification of patients presenting with upper GI bleed was done 
with Rockall score. 20% of population falls with score 0, 38% falls within score 
1 -3, 32% falls within score 4-7 and 10% falls in the score of greater than 7. 
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Table11 Relation between Rockall score and rebleed in study population : 
          Patients           Rebleed P value 
        Frequency Frequency Percentage%   
  0 20 0 0   
Rockall 
score 1-3. 38 0 0   
  4-7. 32 10 31.30% 0.001* 
  >7 10 6 60%   
  Total 100 16 10%   
*Statistically significant 
 
 
 
Chi square test Value Df 
Asymp
. Sig. 
 (2-
sided) 
Exact 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (1-
sided) 
Point 
probabilit
y 
Pearson Chi-Square 
30.990
a 3 0 0     
Likelihood Ratio 34.724 3 0 0     
Fisher's Exact Test 29.539     0   0.001* 
Linear-by-Linear 
Association 
25.671
b 1 0 0 0   
N of Valid Cases 100           
*Statistically significant 
 Risk of rebleed was assessed with Rockall score. Ther was no 
bleed among patients with score 0-3. 10 patients( 31.3%) had rebleed among 22 
with score 4-7. 6 patients( 60%) had rebleed among 10 with score >7. Thus 
rebleed was more with higher score. The association was significant with p 
value 0.000 
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Table12 Relation between Rockall score and mortality in study population  
          Patients           Mortality P value 
        Frequency Frequency Percentage%   
  0 20 0 0   
Rockall 
score 1-3. 38 0 0   
  4-7. 32 2 6.30% 0.001* 
  
>7 10 8 80% 
  
*Statistically significant 
Chi square test Value Df 
Asymp. 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (1-
sided) 
Point 
probability 
Pearson Chi-Square 61.389a 3 0 0     
Likelihood Ratio 40.046 3 0 0     
Fisher's Exact Test 34.852     0     
Linear-by-Linear 
Association 29.470b 1 0 0 0 0 
N of Valid Cases 100           
 
There was no mortality in patients with Rockall score 0 – 3. Among 32 patients 
with score 4-7, 2 patients expired constituting 6.3% mortality. In patients with 
score >7, 8 were dead among 10 constituting 80% mortality. Association 
between rockall score and mortality was significant statistically with P value 
.001 
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Table14 Glasgow Blatchford score among study population  
  
GBScore Frequency Percentage % 
0 26 26 
<5 53 53 
>5 21 21 
Total 100 100 
 
 Risk stratification with Glascow Blatchford score shows 26% 
having score of ‘0’, 53% having score less than 5 and 21% having score greater 
than 5. 
0%
10%
20%
30%
40%
50%
60%
Score 0 Score <5 >5
20%
53%
21%
%
 o
f 
st
u
d
y
 p
o
p
u
la
ti
o
n
Score
Glasgow Blatchford Score among study population
 
86 
 
 
Table15 Relation between Glasgow Blatchford score and rebleed in study 
population 
 
          Patients           Rebleed 
P 
value 
     Chisquare 
test   Frequency Frequency Percentage%   
  0 26 0 0   
Glasgow 
Blatchford 
score <5 53 4 7.50% 0.001* 
  >5 21 12 57.10%   
*statistically significant 
 
 
Chi square test Value Df 
Asymp. 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (1-
sided) 
Point 
probability 
Pearson Chi-Square 34.219a 2 0 0     
Likelihood Ratio 30.89 3 0 0     
Fisher's Exact Test 27.801     0   0.001* 
Linear-by-Linear 
Association 25.815b 1 0 0 0   
N of Valid Cases 100           
 
 Patients with score 0 had no rebleed. There was 4 rebleed among 
53 patients( 7.5%) with score less than 5. 12 rebleed among 21 patients with 
score 21( 57.1%). The association was significant with P value 0.0001  
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Table16 
Relation between Glasgow Blatchford score and mortality in study 
population: 
 
          Patients           Mortality P value 
        
Frequenc
y 
Frequenc
y 
Percentage
%   
  0 26 0 0   
Glasgow 
Blatchford 
score <5 53 0 0 0.001* 
  >5 21 10 47.60%   
  Total 100 10 10%   
 
 
 Comparing glascow Blatchford score and mortality, there was no 
death in patients with score 0 and score less than 5. Among 21 patients with 
score greater than 5, mortality occurred in 10, constituting 47.6% among them. 
P value was significant .000 
Chi square test Value Df 
Asymp. 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (2-
sided) 
Exact 
Sig. 
 (1-
sided) 
Point 
probability 
Pearson Chi-Square 41.799a 2 0 0     
Likelihood Ratio 35.952 2 0 0     
Fisher's Exact Test 30.89     0   0.001* 
Linear-by-Linear 
Association 25.941b 1 0 0 0   
N of Valid Cases 100           
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Table17 Rebleed among study population: 
Rebleed Frequency Percentage % 
Present 16 16 
Absent 84 84 
 
 Rebleed after the initial episode and after diagnostic endoscopic 
procedure was found in 16% patients. 50% of them are due to variceal bleed 
and other 50% are peptic ulcer related. 
 
Mortality among study population : 
           Overall all cause mortality occurred in 10% of study population . 
In this study overall mortality of 9% occurred in males and 1% in females 
among study population. 
Table18 Distribution of mortality in study population 
Sex Patients                  Mortality  
  Frequency Frequency Percentage% 
Male 72 9 12.50% 
Female 28 1 3.60% 
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           Among 72 male patients in this study, death occurred in 9 of them 
constituting 12.5% of death among males. In case of female patients, death 
occurred in one patient constituting 3.6% of female population. 
Table19 Distribution of mortality among various etiology in study 
population : 
 
Diagnosis Patients                  Mortality  
  Frequency Frequency Percentage% 
Varices 36 6 16.70% 
PUD 25 3 12.00% 
Malignacy 7 1 14.30% 
 
  
  In the study population mortality occured in 6 patients (6%)due to 
variceal bleed,  3 patients(3%) due to PUD and and in one patient (1%) due to 
neoplasm. Mortality within each etiology shows 16.7% mortality among 
variceal bleed, 14.3% among neoplasm and 12% among PUD patients.  
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Table20 
Distribution of mortality among co-morbidities in study population : 
 
Diagnosis Patients                  Mortality  
  Frequency Frequency Percentage% 
CKD 7 4 57.00% 
IHD 9 4 44.00% 
HF 3 2 66.70% 
 
 
 Among  study patients who suffered from CKD, mortality was 
57.1%; who had  ischemic  heart disease mortality was recorded in 44.4% and 
among heart failure patients death occurred in 66.7% 
 
 
 
 
 
 
 
 
 
92 
 
Discussion  
 
  The study conducted with aim of finding the pattern of upper GI 
bleed in our locality, the results are analysed and showed similarities and 
variation when compared with similar studies conducted in various parts of 
India. The results analysed are discussed with relation to each variable below. 
Age distribution among study population : 
 Incidence of UGIB in the study population was more among 40 – 
50 years of age, followed by 50 -60 years of age and then 30-40years  of age.
 In a study done by Rathi et al. in Western India the mean age of 
patients presenting with UGIB was 42 years.  In a study by Lakhwani et al. in 
2000, mean age of patients were 51.9 years 
Sex distribution among study population : 
 Male patients comprised 72% of study population and females 
28% of study population. 
  In Deep Anand et al studyUGIB was found to be more common 
in men (83.33%) as compared to women (16.66%)(2). 
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Symptoms distribution among study population : 
 Hematemesis alone was recorded in 48% of patients and melena 
alone was recorded in 19 % of patients. Both occurred in 33 % of study 
population. 
  Deep Anand et all observed  27.19%  of  isolated hematemesis, 64% patients 
presented with complaints of hematemesis and melena, 12.28% isolated melena, 
0.87% patient presented with hematochezia  (2). 
Etiology of upper GI among study population : 
             Analying the etiology of upper GI bleed using upper GI scopy revealed 
varicel bleed as the most common finding constituting  36% of study 
population. Peptic ulcer disease  was the second common cause with 25% of 
study population. Other findings include Erosive gastroduodenal lesions 10%, 
Neoplasm 7%, Mallory weiss tear 6%, Esophagitis 3%, other lesions 2%. No 
identifiable lesion was recorded in 11% of study population. 
 Referral to tertiary care, patients refusal to evaluation of GI bleed 
in cases of  suspected acute erosive gastritis, higher percentage of alcohol 
consumption in the study population might contribute to variceal bleed as most 
common cause. 
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 Study done at Dehradun- Northern india by Deep Anand et all  
revealed 56.14% patients had portal HTN  related esophageal and fundal 
varices, 14.91% had gastric and duodenal ulcer, 12.28% had gastric 
erosions/gastritis, 8.77% had Mallory–Weis tear, 4.38% had gastric 
malignancy(2) 
 Anand et al. from North India, causes of bleeding were 
esophageal varices in 45.5%, duodenal ulcer in 25%, gastric ulcer in 5% and 
gastritis in 8.5%.[12 
 Dilawari et al. found variceal bleeding due to portal hypertension 
(36%) as the most frequent cause followed by peptic ulceration (24%) and 
gastric erosions (19%).[13 
 Differing with other studies, was the one  done at  coastal odisha 
in 2013, most common cause in  endoscopic diagnosis was duodenal ulcer in 
57.6% patients, variceal bleed in 12.8%, gastric ulcer in 1.8% , Mallory–Weiss 
tear in 1.8% , erosive gastritis in 1.8% patients and malignancy comprised of 
7.7%[ 8 
Risk factors : 
 Alcohol was found as risk factor among the population. 44%  
study population had alcohol. 15% had history of NSAIDs intake. 4% had 
Antiplatelet drug. History of  Smoking was recorded in 11% . 
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Comorbidities : 
 The morbidity and mortality was more when associated co morbid 
conditions existed. CKD was recorded in 7%, Ischemic heart disease in 9%, 
Heart failure in 3% of study population.  
Chronic liver disease : 
 Pre-existing liver disease was recorded in 21%( 21 patients) of  
study population. Among 36 patient with variceal bleed, 14( 38.8%)were  new 
patients who had  not been diagnosed to have liver disease previously. The 
initial presenting feature which made them sought medical advice is the UGIB. 
Child pugh score : 
 Severity of liver disease was assessed with Child pugh score in  
patients with variceal bleed. Child pugh score A was found in 15%,score B in 
16% and score C in 5% . 
ROCKALL SCORE : 
 Risk stratification of patients presenting with upper GI bleed was 
done with Rockall score. Risk of rebleed and mortality was found to be 
increased  in patients with score 4-7 and much higher in score >7. 
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 Ther was no re bleed and mortality among patients with score 0-
3.The association was significant with p value 0.001 
 In various validating studies done around the world, Rockall score 
of  0-3 has no intervention needed, score 4-7  had good outcome with minimal 
intervention and score more than 7 had significant hospital stay, rebleed and 
mortality. 
Glasgow Blatchford Score : 
 Risk stratification with Glasgow Blatchford score shows that 
patient with score 0 had no rebleed, no mortality and required no intervention. 
There was no mortality in patients with score less than 5 and less intervention 
was needed. Patients with score >5 had significant rebleed and mortality which 
was statistically significant.  
 In the original study done by Blatchford, the intervention and 
hospital stay was significantly low in score group 0.  
Mortality : 
 Overall mortality occurred in 10% of patients. 6% occurred due to 
variceal bleed, 3% due to peptic ulcer disease and 1% due to neoplasm. 
Mortality within each category revealed higher percent among variceal bleed 
followed by neoplasm.  
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 Mortality was associated more with patients who suffered other 
organ failure.  
 Anand et all study shows overall mortality of 21% among study 
population, with portal hypertensive group being the common followed by 
peptic ulcer disease. 
 In a study by Chalasani et al.[22] a total of 231 subjects were 
included, and their in‑hospital, 6‑week, and overall mortality rates were 14.2%, 
17.5%, and 33.5%, respectively 
 
Limitations of the study : 
         This study has its own limitations. The study was conducted with minimal 
sample population.  The time of presentation varied among patients and 
subsequently the timing of endoscopy evaluation and intervention.  Outcome of 
the study is influenced by patients who did not consent or did not undergo upper 
GI scopy. 
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Summary 
 
              This study done in our hospital,a tertiary care center to southern part of 
the state, revealed that the most common cause of Upper Gastrointestinal 
bleeding was Varices. The second most common cause was Peptic ulcer related 
bleed. The other causes in descending order of frequency were Erosive 
gastroduodenal lesions, Neoplasm, Mallory-Weiss tear, Esophaghitis, Vascular 
lesions.   
               Alcohol being the associated risk factor in variceal bleed, accounted 
for common cause in portal hypertension. This reflects the burden of alcohol 
consumption on health issues. 
              This study revealed sex ratio of  male to female 2.5:1. Male patients in 
the study was comprised of  72% 
              This study shows the majority of patients(29%) fall in the age group of 
40-50 years, followed by 50-60years of age(25%). 
              Among the study population, the patients who had melena had 
statistically significantly asscociation with mortality. Mortality occurred in 
patients who had hematemesis alone, but significant association could not be 
established. 
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              In this study,risk of rebleed and mortality was significantly absent in 
patients with ROCKALL score of 0-3 and Glasgow Blatchford score of 0 .  
The risk was significantly increased with higher scores in both the system. 
            Among the study population, factors associated with mortality were 
presence of co-morbidities like renal failure and cardiac failure. Mortality was 
associated with Rockall score of  >7 and Glasgow Blatchford score of >5 which 
were statistically significant.  
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Conclusion  
 
 
        1. Variceal bleed is the most common cause in this study reflecting upon 
the population of this region. 
        2. Small percent of  liver disease manifested with upper gastrointestinal 
bleed as initial presentation.  
        3.Patient risk stratification for intervention and can be  prioritised with 
scoring system. Prognosis is poor  in patients with co-morbidities and with 
higher score in scoring system.  
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 PROFORMA 
 
 
Name : 
Age / sex :            IP.No : 
Residence :        Ward : 
Occupation :     
Socioeconomic status : 
 
Complaints of :     duration : 
 
Present complaints: 
 
H/o haemetemesis  
    duration  
           no. of episodes 
  amount of blood in vomitus 
H/o melena 
  duration  
H/o epigastric pain  
H/o fever 
H/o other bleeding manifestations 
H/o loss of appetite / weight  
 
 
 
106 
 
 
Personal h/o : 
H/o alcohol intake  
           years                         amount/week                              last 
intake 
H/o smoking  
 
Past h/o : 
H/o NSAIDS / drug intake  
H/o DM 
H/o Hypertension 
 H/o coexisting diseases 
 
General examination: 
Vitals : 
 Pulse : 
 BP : 
 
 
Systemic examination: 
 
  ABDOMEN 
 CVS 
 RS 
 CNS 
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Investigations: 
 
Hb 
TC             DC  
Platelet count 
RBS 
LFT 
       SGOT    SGPT   ALP     S.Bilirubin    S.Proteins  
       PT               INR 
 
RFT 
 
ULTRASOUND ABDOMEN : 
 
UPPER GI SCOPY :  
 
 
Rockall score : 
Glasgow Blatchford score : 
Child pugh score : 
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Abbrevations : 
 
CLD – Chronic liver disease 
EST – Endoscopic sclerotherapy 
EVL – Endoscopic variceal ligation 
GI – Gastrointestinal 
GBS – Glasgow Blatchford score 
NSAIDs – Non steroidal anti inflammatory drugs 
OGD – oesophago gastro duodenoscopy 
PPI – Proton pump inhibitors 
PUD – Peptic ulcer disease 
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Master chart : 
Name Age sex 
Hemat 
emesis Melena 
OGD 
 
finding Alcohol NSAIDs 
Anti 
platelet Smoking 
Co 
morbidity 
Pre 
existing 
CLD 
Child 
pugh 
score 
Rockall 
score GBS Rebleed Mortality 
Mayandi 5 1 1 0 1 0 0 1 0 2 1 1 2 2 1 0 
Mariappan 4 1 1 1 2 0 0 0 0 0 0 0 2 2 1 0 
Nallamal 5 2 0 1 4 0 1 0 0 1 0 0 1 2 0 0 
Balusamy 5 1 0 1 2 0 1 0 0 0 0 0 0 2 0 0 
Govindhan 5 1 1 1 1 1 0 0 0 0 1 1 2 3 1 0 
Karuppu 4 1 1 0 1 1 0 0 0 0 1 2 1 2 0 0 
Bachiyam 3 2 1 1 2 0 0 0 0 0 0 0 1 2 0 0 
Deepa 1 2 1 0 8 1 0 0 0 0 0 0 0 1 0 0 
Murugan 3 1 1 0 6 1 0 0 1 0 0 0 1 2 0 0 
Kalyani 4 1 0 1 1 1 0 0 0 0 0 1 1 2 0 0 
Harimurugan 4 1 1 0 1 1 0 0 0 0 0 1 1 2 0 0 
Panjan 5 1 1 0 2 1 0 0 1 0 0 0 0 1 0 0 
Raja 2 1 1 1 5 1 0 0 0 0 0 0 0 1 0 0 
Alagarsamy 7 1 1 1 2 0 1 0 0 1 0 0 3 3 1 1 
Kumar 3 1 1 0 4 1 0 0 0 0 0 0 0 2 0 0 
Thiru 4 1 1 0 5 1 0 0 0 0 0 0 0 2 0 0 
Kanagaraj 6 1 1 1 1 1 0 0 0 3 1 2 3 3 1 1 
Rakammal 4 2 1 0 2 0 1 0 0 0 0 0 1 2 0 0 
Saleem 4 1 1 0 3 0 0 0 1 0 0 0 1 1 0 0 
Pitchai 6 1 1 1 6 1 0 0 1 2 0 0 3 3 0 1 
Indurani 6 2 1 0 1 0 0 0 0 0 0 2 2 2 0 0 
Karthik 3 1 0 1 3 0 0 0 0 0 0 0 1 1 0 0 
Irulappan 6 1 0 1 2 0 0 1 0 2 0 0 2 2 0 0 
Kandappan 4 1 1 0 2 0 0 0 0 0 0 0 0 1 0 0 
yasodhai 5 2 0 1 1 0 0 0 0 0 0 1 2 2 0 0 
Chinnakutty 6 1 1 1 1 0 0 0 0 2 1 3 3 3 1 1 
Rajendran 5 1 1 0 3 0 0 1 0 0 0 0 1 2 0 0 
Arumugam 3 1 1 0 7 0 0 0 0 0 0 0 0 1 0 0 
Lilysiromani 5 2 1 1 7 0 0 0 0 0 0 0 2 2 0 0 
Pappathi 2 2 1 0 5 0 0 0 0 1 0 0 1 2 0 0 
Prabanjan 2 1 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Lakshmi 7 2 1 1 2 0 0 0 0 1 0 0 3 3 1 1 
Amutha 3 2 1 1 1 1 0 0 0 0 0 1 1 2 0 0 
Indra 2 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Palanisamy 5 1 1 1 6 1 0 0 1 0 0 0 2 2 0 0 
Arumugam 4 1 1 1 1 1 0 0 0 0 1 2 2 2 0 0 
yogapriya 1 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Arumugam 4 1 0 1 1 1 0 0 0 2 1 2 2 2 0 0 
Rangan 4 1 1 0 1 0 0 0 0 0 0 1 1 2 0 0 
kumar 3 1 1 0 8 0 0 0 0 0 0 0 1 1 0 0 
sumathi 2 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Muthusamy 5 1 0 1 2 0 1 0 0 1 0 0 2 3 1 1 
Karuppaiya 4 1 1 1 1 1 0 0 0 0 0 1 1 2 0 0 
Narayanan 5 1 1 1 1 1 0 0 1 2 1 2 3 3 0 1 
Rajesh 2 1 1 1 2 1 0 0 0 0 0 0 1 1 0 0 
Muthu 2 1 1 0 3 1 0 0 0 0 0 0 1 1 0 0 
Alagarsamy 5 1 1 0 6 1 0 0 1 0 0 0 2 2 0 0 
karuppu 5 1 0 1 1 1 0 0 1 3 1 2 3 3 1 1 
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Mohan 4 1 1 0 1 1 0 0 0 0 0 2 2 2 0 0 
Rajesh 5 1 0 1 1 1 0 0 0 0 1 3 2 3 0 0 
Naveen 3 1 1 1 5 1 0 0 0 0 0 0 1 2 0 0 
Samikannu 4 1 1 1 2 0 1 0 0 1 0 0 3 3 1 0 
Paulsamy 3 1 1 0 4 1 0 0 0 0 0 0 0 1 0 0 
Gopinathan 3 1 1 0 5 1 0 0 0 0 0 0 1 2 0 0 
Savarimuithu 5 1 0 1 1 1 0 0 0 0 1 3 2 3 1 0 
Sathish 4 1 1 0 2 1 0 0 0 0 0 0 0 1 0 0 
Pitchaikani 5 1 1 0 1 0 0 0 0 0 1 2 2 3 0 0 
Hanifa 5 1 1 1 6 1 0 0 1 2 0 0 2 3 0 0 
Balamurugan 4 1 1 0 1 0 0 0 0 0 0 1 2 2 0 0 
Chinthamani 3 2 0 1 3 0 1 0 0 0 0 0 1 2 0 0 
Sandhiya 3 2 0 1 2 0 0 0 0 0 0 0 1 2 0 0 
Selvi 2 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Ganga 3 2 0 1 3 0 1 0 0 0 0 0 1 2 0 0 
Pandi 4 1 1 1 1 0 0 0 0 0 0 1 2 2 0 0 
Subbaiya 5 1 1 1 2 0 1 0 0 0 0 0 2 2 1 0 
Moorthy 3 1 1 0 5 0 0 0 0 0 0 0 0 1 0 0 
Dinesh 2 1 1 1 3 0 0 0 1 0 0 0 1 1 0 0 
Muthupandi 4 1 1 0 1 1 0 0 0 0 1 2 3 3 0 0 
Selvam 3 1 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Rangasamy 4 1 1 1 2 0 0 0 0 0 0 0 1 2 0 0 
Meena 3 2 1 1 1 0 0 0 0 0 1 2 2 3 0 0 
Aruna 3 2 1 0 3 0 1 0 0 0 0 0 1 1 0 0 
Rani 4 2 1 1 6 0 0 0 0 0 0 0 2 2 0 0 
Sundaram 4 1 1 1 1 1 0 0 0 0 0 2 2 3 1 0 
banu 3 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Nagarajan 5 1 1 1 1 1 0 0 0 1 1 3 2 3 0 1 
Mohan 4 1 1 0 1 1 0 0 0 0 1 2 2 2 0 0 
Dhavamani 6 1 0 1 2 0 0 0 0 0 0 0 1 2 0 0 
Vijayan 4 1 1 1 2 0 1 0 0 0 0 0 2 2 1 0 
Shahul 3 1 1 1 1 1 0 0 0 0 0 1 2 2 0 0 
Arunkumar 2 1 1 0 2 1 0 0 0 0 0 0 1 1 0 0 
Chandra 3 2 0 1 2 0 1 0 0 0 0 0 1 2 0 0 
Kandhasamy 4 1 1 0 6 0 0 0 1 0 0 0 1 2 0 0 
kalimuthu 3 1 1 0 1 1 0 0 0 0 1 1 2 2 0 0 
Kannamma 5 2 1 0 2 0 0 0 0 0 0 0 0 1 0 0 
Gurusamy 5 1 0 1 2 0 1 0 0 3 0 0 2 3 1 0 
Muthammal 4 2 1 0 3 0 1 1 0 2 0 0 1 2 0 0 
Krishnan 3 1 1 1 1 1 0 0 0 0 0 1 1 2 0 0 
Veeraiyan 6 1 0 1 1 1 0 0 0 2 1 3 3 3 0 1 
Palaniyamal 5 2 1 1 2 0 1 0 0 0 0 0 1 2 0 0 
Chitra 3 2 1 0 8 0 0 0 0 0 0 0 1 2 0 0 
Palani 4 1 1 0 1 1 0 0 0 0 1 2 2 2 0 0 
Devi 2 2 1 0 8 0 0 0 0 0 0 0 0 1 0 0 
Thangarasu 5 1 1 0 2 0 0 0 0 0 0 0 1 2 0 0 
Senthil 4 1 1 0 1 1 0 0 0 0 1 2 1 2 0 0 
Manikkam 5 1 1 1 1 1 0 0 0 0 1 2 2 3 1 0 
Ajith 2 1 1 0 3 1 0 0 0 0 0 0 1 1 0 0 
Pandiselvi 4 2 1 0 2 0 0 0 0 0 0 0 1 2 0 0 
Duraisamy 4 1 0 1 1 0 0 0 0 0 0 1 1 2 0 0 
Veerasamy 5 1 1 1 1 1 0 0 0 0 0 1 2 2 0 0 
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Key to Master chart : 
Age :  
1- less than 20 years  
2  - 21 to 30 years old 
3  -  31 to 40 years old 
4 -   41 to 50 years old 
5 -  51 to 60 years old 
6 -  61 to 70 years old 
7 -  greater than 70 years of age 
Sex:  1 – Male ; 2 – Female 
Hematemesis : 0 –  Absent ;  1 – Present 
Melena :  0 –  Absent ;  1 – Present 
Risk factors :  0 –  Absent ;  1 – Present 
Comorbidity : 1 – CKD,  2-IHD, 3- HF 
Child pugh score : 0 – Not applicable;  1- class A, 2- class B 3-class C 
Rockall score: 0 – score ‘0’ ;      1 - score ‘1to3’;    2-score ‘4-7’; 
         3-score >7 
Glasgow Blatchford score: 1- score ‘0’        ; 2 – score ‘<5’ ;        3 – score ‘>5’ 
Rebleed:   0 – Absent;  1-Present 
Mortality:  0 – Absent;  1-Present 
 
